GlassScriptPhysician profile
Shaukat Ali
NPI 1700956844
$8,845.22
in general payments reported to CMS, 2019-2025
41 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $917 · 2021: $1,137 · 2022: $1,292 · 2023: $1,431 · 2024: $1,680 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,854 · Education: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,854.19 |
| Education | $617.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,364.26 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $984.42 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $896.78 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $879.92 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $515.15 | 2021-2024 | |
| Akebia Therapeutics INC | $513.83 | 2019-2022 | |
| Travere Therapeutics, INC. | $477.18 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $350.27 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $323.30 | 2019-2025 | |
| Ardelyx, INC. | $298.32 | 2023-2025 | Ibsrela |
| Amgen INC. | $292.00 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $263.89 | 2019-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $212.89 | 2022-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $161.32 | 2019 | |
| Glaxosmithkline, LLC. | $160.20 | 2022-2024 | Jesduvroq, Benlysta |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaukat Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.